Compass Therapeutics (NASDAQ:CMPX) Sets New 52-Week High – Time to Buy?

Compass Therapeutics, Inc. (NASDAQ:CMPX) reached a new 52-week high during trading on Monday . The company traded as high as $3.95 and last traded at $3.94, with a volume of 359782 shares changing hands. The stock had previously closed at $3.50.

Wall Street Analyst Weigh In

A number of analysts recently commented on CMPX shares. Leerink Partners cut shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $5.00 to $4.00 in a research report on Friday, November 15th. Leerink Partnrs lowered Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. D. Boral Capital reiterated a “buy” rating and issued a $32.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Compass Therapeutics in a report on Wednesday, January 8th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Compass Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $11.80.

Compass Therapeutics Stock Up 11.9 %

The stock has a fifty day moving average price of $2.07 and a two-hundred day moving average price of $1.72. The company has a market cap of $538.66 million, a price-to-earnings ratio of -10.61 and a beta of 1.17.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.03. Analysts predict that Compass Therapeutics, Inc. will post -0.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in CMPX. Sequoia Financial Advisors LLC bought a new position in Compass Therapeutics in the 4th quarter valued at approximately $45,000. Independent Advisor Alliance bought a new position in shares of Compass Therapeutics during the fourth quarter valued at $26,000. Bank of New York Mellon Corp lifted its holdings in shares of Compass Therapeutics by 2.6% during the fourth quarter. Bank of New York Mellon Corp now owns 237,975 shares of the company’s stock worth $345,000 after purchasing an additional 6,041 shares during the period. Rhumbline Advisers grew its stake in shares of Compass Therapeutics by 3.1% in the fourth quarter. Rhumbline Advisers now owns 129,116 shares of the company’s stock worth $187,000 after purchasing an additional 3,822 shares during the last quarter. Finally, Bleakley Financial Group LLC increased its holdings in Compass Therapeutics by 250.7% in the fourth quarter. Bleakley Financial Group LLC now owns 39,993 shares of the company’s stock valued at $58,000 after purchasing an additional 28,589 shares during the period. 68.43% of the stock is owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.